Circulating cancer biomarkers provide valuable information in detecting and diagnosing cancer. They may also help in predicting patient outcomes and treatment response. However, melanoma currently lacks a reliable blood‐based biomarker of disease activity. But researchers believe that circulating tumor DNA (ctDNA) may fill this role.
According to the National Cancer Institute (NCI), there were 91,270 new cases of melanoma in 2018, making up more than 5% of all new cancer cases. There were 9,320 estimated deaths in 2018, and 91.8% of patients survive five years or longer.
In a recent study, researchers at the Johns Hopkins Kimmel Cancer Center explored the clinical utility of integrating ctDNA data (i.e., impacts on patient management and outcomes) for patients with melanoma in a real‐world setting. They found that measuring and monitoring tumor DNA that naturally circulates in the blood of melanoma patients can not only reliably help reveal the early stages of cancer growth and spread but also uncover new treatment options that tumor genetic analysis alone may not.
“For some patients in our study, circulating tumor DNA (ctDNA)* levels measured in a relatively simple blood test revealed tumor mutations that could be potentially targeted with current or new drugs that inhibit tumor growth mutations that are not revealed by genetic profiling of the tumor itself,” noted Evan Lipson, M.D., an associate professor of oncology at the Kimmel Cancer Center and a member of The Bloomberg-Kimmel Institute for Cancer Immunotherapy.
“For other patients, ctDNA levels accurately predicted disease progression as seen on CT scans, further demonstrating ctDNA’s role as a blood-based biomarker of disease activity in melanoma patients.”
Improving Outcomes Melanoma currently lacks a consistently and wholly reliable predictive blood-based biomarker of disease progression. Having one, Lipson says, would not only improve treatment outcomes but also reduce unnecessary or ineffective therapies.
For the study, published in the October 2018 issue of Molecular Oncology, the Kimmel Cancer Center scientists analyzed blood-based ctDNA from 119 different and advanced-melanoma Johns Hopkins patients. The patients were divided into three groups based on the type of tumor they had and potential mutations that were common and reoccurring in those tumors.
The first group of 60 people were patients with radiographically measurable metastatic melanoma, regardless of tumor mutation status. In this group, ctDNA testing revealed a targetable mutation in 38 of the 60 patients. In 33 of those patients, the mutations found using ctDNA matched the mutations found in tumor specimens. In two patients, ctDNA testing revealed a mutation that tumor testing had not.
In the second group, there were 29 patients with surgically removed high-risk (stage IIB-IV) melanoma whose tumor tissue revealed any of the seven common mutations. In this group, none of the patients whose melanoma tumors were surgically removed had evidence of disease before the study. However, five of 29 patients were discovered to have recurrent melanoma during the study, and in two of those cases, ctDNA was detected.
The third group had 30 patients who were receiving or had received therapy for advanced melanoma and had any of the seven common mutations. Of the 30, 17 experienced partial or complete response to therapy, which was confirmed using CT scans over 8, 14, 25 and 38 week periods, and no ctDNA was found in those patients after an initial CT scan evaluation. In the remaining 13 patients, ctDNA was detected during their treatment. In four of those 13, the disease was detected simultaneously by a CT scan and ctDNA results. In four others, ctDNA results predicted disease progression that was confirmed by using CT scan.
“When genetic testing of the tumor alone was used for some of the patients, it did not reveal any option for targeted therapy,” Lipson says.
“It turned out that when we looked in the bloodstream, lo and behold, we found ctDNA that uncovered options for therapy that provided benefit for patients and that otherwise were not going to be used,” Lipson added.
Lipson also notes that in general, melanoma patients receiving treatment typically have CT scans performed months apart over time to compare the growth or regression of the tumors. By using repeated ctDNA blood test results that reflect tumor activity in conjunction with those scans, the researchers say the biomarker was predictive of eventual disease progression seen on CT scans.
According to the researchers, these findings add to evidence that ctDNA testing may help radiologists and oncologists better interpret results of tests and treatments in patients with advanced melanoma. They strongly believe that the study results demonstrate that incorporating ctDNA assessments into real‐world melanoma patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.
Lipson said while larger trials will be needed to further investigate and confirm the findings, evidence is growing that using ctDNA can refine therapeutic outcomes and uncover additional avenues for therapy for some patients with melanoma.
“Our findings may serve as a blueprint for future, randomized investigations designed to further evaluate the clinical utility of incorporating ctDNA analysis among larger groups of patients with melanoma,” Lipson concluded.
The research was supported by Sysmex Inostics, the Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Barney Family Foundation, Moving for Melanoma of Delaware, the Laverna Hahn Charitable Trust, the Roland Park Country School and the National Cancer Institute.
 Rowe SP, Luber B, Makell M, Brothers P, Santmyer J, Schollenberger MD, Quinn H, et al. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol. 2018 Oct;12(10):1661-1672. doi: 10.1002/1878-0261.12373. Epub 2018 Sep 8. [PubMed][Article]
*Circulating tumor DNA of ctDNA is tumor-derived fragmented DNA in the bloodstream that is not associated with cells. ctDNA is rapidly cleared from the blood stream and can generally be obtained by minimally invasive methods. It can be used as a dynamic cancer biomarker for cancer early detection, diagnosis, and treatment monitoring. Despite the potential for clinical use, few ctDNA assays have been cleared or approved by the U.S. Food and Drug Administration (FDA). ctDNA should not be confused with cell-free DNA, a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin.
Last Editorial Review: November 27, 2018
Featured Image: Patient | Scan Courtesy: 2018 © Fotolia. Used with permission. Figure 1.0: Evidence of disease activity detected in circulating tumor DNA (ctDNA) predicts radiographic melanoma progression. Courtesy: 2018 © the Johns Hopkins Kimmel Cancer Center. Used with permission.
Copyright © 2010 – 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.